Published in J Clin Oncol on June 01, 2005
Safety Study of Capecitabine With Radiation in Elderly Rectal Cancer | NCT01584544
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Surgical treatment of colon cancer in patients aged 80 years and older : analysis of 31,574 patients in the SEER-Medicare database. Cancer (2012) 1.45
Use of geriatric assessment for older adults in the oncology setting: a systematic review. J Natl Cancer Inst (2012) 1.42
Decision making and quality of life in the treatment of cancer: a review. Support Care Cancer (2008) 1.19
Are we undertreating rectal cancer in the elderly? An epidemiologic study. Ann Surg (2007) 1.10
Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. J Oncol Pract (2009) 1.10
Predictors of multivisceral resection in patients with locally advanced colorectal cancer. Ann Surg Oncol (2008) 1.00
Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy. Cancer (2014) 1.00
Differences in the symptom experience of older versus younger oncology outpatients: a cross-sectional study. BMC Cancer (2013) 0.98
Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review. Ann Oncol (2013) 0.97
Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat (2012) 0.88
Latent Class Analysis Reveals Distinct Subgroups of Patients Based on Symptom Occurrence and Demographic and Clinical Characteristics. J Pain Symptom Manage (2015) 0.87
Pancreatic cancer: surgery is a feasible therapeutic option for elderly patients. World J Surg Oncol (2011) 0.84
How to implement a geriatric assessment in your clinical practice. Oncologist (2014) 0.82
Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials. Am J Clin Oncol (2016) 0.82
Assessment of cancer care in Indian elderly cancer patients: A single center study. South Asian J Cancer (2013) 0.80
Assessment of solid cancer treatment feasibility in older patients: a prospective cohort study. Oncologist (2014) 0.79
Management of pancreatic adenocarcinoma in Ontario, Canada: a population-based study using novel case ascertainment. Can J Surg (2011) 0.79
Research in cancer care disparities in countries with universal healthcare: mapping the field and its conceptual contours. Support Care Cancer (2014) 0.76
Age differences in fatigue, decrements in energy, and sleep disturbance in oncology patients receiving chemotherapy. Eur J Oncol Nurs (2016) 0.75
Optimal management of colorectal liver metastases in older patients: a decision analysis. HPB (Oxford) (2014) 0.75
The impact of age at diagnosis on socioeconomic inequalities in adult cancer survival in England. Cancer Epidemiol (2015) 0.75
Analysis of the Clinicopathological Characteristics of Gastric Cancer in Extremely Old Patients. Cancer Res Treat (2016) 0.75
Clinicopathological features and prognoses in younger and older patients with gastric cancer. Onco Targets Ther (2017) 0.75
The Perceptions and Expectations of Older Women in the Establishment of the Senior Women's Breast Cancer Clinic (SWBCC): a Needs Assessment Study. J Cancer Educ (2017) 0.75
Mixed method exploration of the medical, service-related, and emotional reasons for emergency room visits of older cancer patients. Support Care Cancer (2015) 0.75
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
An open letter to The BMJ editors on qualitative research. BMJ (2016) 7.49
The case for knowledge translation: shortening the journey from evidence to effect. BMJ (2003) 5.41
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum (2002) 4.69
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med (2015) 4.49
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 4.36
Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum (2002) 4.23
Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA (2003) 4.01
Tumour heterogeneity in the clinic. Nature (2013) 3.92
Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol (2013) 3.76
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst (2005) 3.73
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
Predictors of infection in rheumatoid arthritis. Arthritis Rheum (2002) 3.47
The statins as anticancer agents. Clin Cancer Res (2003) 3.36
Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol (2005) 3.34
Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol (2006) 3.31
30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst (2005) 3.26
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol (2007) 3.16
Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis (2004) 3.11
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst (2005) 3.07
Can we systematically review studies that evaluate complex interventions? PLoS Med (2009) 3.04
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol (2005) 2.83
Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid (2009) 2.79
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol (2011) 2.57
Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. J Natl Cancer Inst (2012) 2.57
Medication reconciliation at hospital discharge: evaluating discrepancies. Ann Pharmacother (2008) 2.57
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol (2005) 2.52
Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst (2012) 2.46
Impact of wait times on survival for women with uterine cancer. J Clin Oncol (2013) 2.45
Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst (2002) 2.44
Using cancer registry data for survival studies: the example of the Ontario Cancer Registry. J Clin Epidemiol (2005) 2.43
Nasopharyngeal carcinoma: the next challenges. Eur J Cancer (2010) 2.04
Randomized phase II trials: inevitable or inadvisable? J Clin Oncol (2010) 2.02
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol (2012) 1.95
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.93
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol (2007) 1.91
Strategies for rehabilitation professionals to move evidence-based knowledge into practice: a systematic review. J Rehabil Med (2009) 1.90
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res (2003) 1.82
Designing transformative clinical trials in the cancer genome era. J Clin Oncol (2013) 1.79
Dermopathy of Graves' disease (pretibial myxedema): long-term outcome. J Clin Endocrinol Metab (2002) 1.73
Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol (2003) 1.71
First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol (2008) 1.70
Cancer genomics: technology, discovery, and translation. J Clin Oncol (2012) 1.70
Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol (2005) 1.69
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. Clin Cancer Res (2006) 1.63
Response audit of an Internet survey of health care providers and administrators: implications for determination of response rates. J Med Internet Res (2008) 1.63
The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease. J Am Soc Nephrol (2002) 1.60
Association between chronic cerebrospinal venous insufficiency and multiple sclerosis: a meta-analysis. CMAJ (2011) 1.59
Pharmacist medication assessments in a surgical preadmission clinic. Arch Intern Med (2007) 1.57
Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther (2005) 1.57
Population based survival data on urachal tumors. J Urol (2006) 1.55
A scoping review of patient discharge from intensive care: opportunities and tools to improve care. Chest (2015) 1.55
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer (2011) 1.55
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol (2007) 1.53
Using administrative databases to measure waiting times for patients undergoing major cancer surgery in Ontario, 1993-2000. Can J Surg (2005) 1.49
Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int J Cancer (2012) 1.49
Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.49
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol (2012) 1.48
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res (2008) 1.44
An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am (2008) 1.44
Translation of evidence into a self-management tool for use by women with urinary incontinence. Age Ageing (2011) 1.43
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res (2008) 1.43
A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res (2008) 1.42
Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. BMC Cancer (2006) 1.41
Systematic reviews: time to address clinical and policy relevance as well as methodological rigor. Ann Intern Med (2007) 1.40
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol (2007) 1.40
It's time to take back the health care debate. CMAJ (2007) 1.38
A systematic review of interventions to increase breast and cervical cancer screening uptake among Asian women. BMC Public Health (2012) 1.38
Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol (2012) 1.38
Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res (2010) 1.35
Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer (2006) 1.33
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol (2010) 1.31
Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol (2006) 1.29
Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol (2007) 1.28
Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. J Clin Oncol (2013) 1.28
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer (2007) 1.27
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res (2007) 1.26
Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood (2005) 1.24
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs (2014) 1.23
Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials. J Clin Oncol (2010) 1.23
Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction. Am J Pathol (2004) 1.21
A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance. J Magn Reson Imaging (2014) 1.21
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol (2014) 1.20
Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst (2007) 1.20